NY-IFF
2.6.2022 22:17:09 CEST | Business Wire | Press release
IFF (NYSE:IFF) has released its 2021 environmental, social and governance plus sustainable solutions (or ESG+) performance report. Published today, “Transforming Our World ,” details the Company’s commitment to do more good for people and the planet, aligned with IFF’s purpose—Applying science and creativity for a better world. Centered around the recently launched Do More Good Plan , the report updates progress on legacy IFF targets, looks ahead to even more ambitious 2030 objectives, and aims to address the world’s most pressing sustainable development challenges from IFF’s perspective.
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET.
“At IFF, we’re taking a holistic approach to creating a better world by leveraging our business, performance and partners,” said Frank Clyburn, IFF CEO. “Since the launch of our first sustainability program in 2010, we’ve made tremendous progress. To continue driving results, we’re challenging our teams to be accountable, to collaborate across divisions, and to execute on our ESG+ strategy.”
“At today’s IFF, we’re taking another bold step, embedding a more comprehensive ESG structure in every part of our business, including the solutions we produce to help our customers reach their own ESG goals,” Mr. Clyburn continued. “Following the merger with DuPont’s Nutrition and Biosciences division, this report showcases our first year of results since launching our Do More Good Plan. We’re proud of the many ways we’re becoming a stronger, more resilient company, as we apply science and creativity for a better world.”
The 2021 ESG+ Report aligns with the Do More Good Plan’s four pillars: Sustainable Solutions, Climate and Planetary Health, Equity and Wellbeing, and Transparency & Accountability.
Examples of 2021 performance highlights and achievements include:
- Recognized for ESG leadership: named to the Dow Jones Sustainability Indices for the second consecutive year, received the EcoVadis platinum sustainability rating, and included in the Bloomberg Gender Equality Index
- Enabled and accelerated the wider adoption of sustainable solutions in the marketplace across divisions, and promoted circular economy growth through IFF products verified as Upcycled Certified™
- Continued commitment to climate action—being one of only 14 companies out of nearly 12,000 assessed—named by CDP as a triple A list company for corporate transparency on climate change, water stewardship and deforestation
- Strengthened commitment to diversity, equity and inclusion, honored by the Human Rights Campaign as a Best Place to Work for LGBTQ Equality for the third consecutive year, and named among the Best Places to Work for Disability Inclusion by Disability:IN for the second consecutive year
To read IFF’s 2021 ESG+ Report, click here or visit: https://www.iff.com/responsibilities/strategy-reporting/report-library .
Webcast
A live webcast to discuss the Company’s Do More Good Plan and goals, 2021 ESG+ metrics and performance results, and 2022 outlook will be held on June 9, 2022 at 8:00 a.m. ET. Mr. Clyburn will be joined by Michael DeVeau, Chief Investor Relations & Communications Officer; Dr. Greg Yep, Chief Research & Development, Global Integrated Solutions and Sustainability Officer; Pete Sommers, Interim Chief Human Resources and Diversity, Equity & Inclusion Officer; and Kip Cleverley, Vice President, Global Sustainability & EHS. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com .
Investors and analysts are invited to participate by phone by calling 866-342-8591 from the United States and 203-518-9713 from other locations. The access code for the conference call is IFF0609. A live listen-only webcast will also be available at ir.iff.com . For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.
Welcome to IFF
At IFF (NYSE: IFF)—an industry leader in food, beverage, scent, health and biosciences—science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom